RxDoctor Payments Data

Anupama Rao, MD

Cardiovascular Disease · Baltimore, MDNPI 1255399481

Payments from drug & device makers

$4,210in general payments, 2019–2025

Across 65 payments — averaging $64.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Bridgebio Pharma, Inc.$2K
  • Amgen$303
  • Pfizer$167
  • Heartflow, Inc.$164
  • Kestra Medical Technology Services, Inc.$80
  • plus $456 from 14 others

What the payments were for

  • Consulting fees$2,90569%
  • Food & beverage$1,30531%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,210 in reported general payments places this provider in the 65th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$79,925
Medicare patients
978
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$60,947
FarxigaDapagliflozin Propanediol43$30,399
Repatha SureclickEvolocumab31$18,127
EntrestoSacubitril/Valsartan17$17,184
Praluent PenAlirocumab17$7,898
Rosuvastatin Calcium58$825
Metoprolol Succinate38$629
Atorvastatin Calcium48$543
Ezetimibe22$395
Potassium Chloride22$352
Pravastatin Sodium23$237
Labetalol Hcl11$170
Amlodipine Besylate35$138
Losartan Potassium19$122
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med12$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$167$60,94764 claims
AstraZenecaFarxiga$19$30,39943 claims
NovartisEntresto$40$17,18417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →